Using imaging to predict cancer response in rectal cancer patients
A Multi-center Study on Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University · NCT06719414
This study is testing a special type of MRI to see if it can help predict how well rectal cancer patients respond to treatment before they have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 320 (estimated) |
| Sex | All |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University (other) |
| Locations | 2 sites (Guangzhou, Guangdong and 1 other locations) |
| Trial ID | NCT06719414 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of amide proton transfer-weighted imaging in predicting the pathological complete response of rectal cancer patients after they have undergone neoadjuvant therapy. Participants will receive this imaging technique as part of their routine MRI examinations to assess how well their cancer responds before surgical intervention. The study focuses on patients with locally advanced rectal cancer who are eligible for surgery following neoadjuvant treatment.
Who should consider this trial
Good fit: Ideal candidates include patients with locally advanced, resectable rectal adenocarcinoma who have received neoadjuvant therapy.
Not a fit: Patients with poor image quality, prior treatments for rectal cancer, or those who cannot undergo MRI examinations will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive method to predict treatment outcomes for rectal cancer patients, potentially guiding surgical decisions.
How similar studies have performed: While the specific use of amide proton transfer-weighted imaging in this context may be novel, similar imaging techniques have shown promise in predicting treatment responses in other cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Locally advanced rectal cancer(cT3-4, or cN+), resectable, histologically confirmed rectal adenocarcinoma * Received neoadjuvant therapy before surgery * Complete radical resection of rectal cancer and postoperative pathological examination * Informed consent and signed the informed consent form Exclusion Criteria: * Poor image quality, such as severe artifacts * Complicated with intestinal obstruction, intestinal perforation and other cases requiring surgical treatment * The interval between preoperative MRI and surgery was more than 2 weeks * Prior treatment for rectal cancer * History of other malignant tumors * Patients who cannot undergo MRI examination due to contraindications or relative contraindications * Patients were lost to follow-up or voluntarily withdrew from the study due to adverse reactions or other reasons
Where this trial is running
Guangzhou, Guangdong and 1 other locations
- Sixth Affiliated Hospital, Sun Yat-sen University — Guangzhou, Guangdong, China (RECRUITING)
- Xinyi People's Hospital — Maoming, Guangdong, China (NOT_YET_RECRUITING)
Study contacts
- Study coordinator: Peiyi Xie
- Email: xiepy6@mail.sysu.edu.cn
- Phone: 86+13724071514
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Rectal Cancer